ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

January 9, 2026 updated by: American Thrombosis and Hemostasis Network

ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders

In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.2,3,4,5

In 2019 alone, the FDA has issued approvals for 24 new therapies for congenital and acquired hematologic conditions.6 In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.7

With this increase in potential new therapies possible, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.8

Study Overview

Status

Recruiting

Conditions

Detailed Description

This is a longitudinal, natural history observational cohort study being conducted at approximately 150 ATHN-affiliated sites with a target accrual of 3,000 participants. Participants will be followed for a minimum of 15 years on an assigned arm within a cohort; however, arm or module participation may last longer, and participants will continue participation in the arm or module for its duration. Harmonized data elements will be collected at the time of enrollment, semi-annually (every 6 months), annually, ad hoc, and as defined by the terms of individual arms and modules. Data will be collected for participants enrolled in cohort-specific arms and modules.

Each participant will be assigned to a single cohort: Hemophilia, von Willebrand Disease, Congenital Platelet Disorders, Rare Disorders, Bleeding Not Otherwise Specified (NOS), Thrombosis/Thrombophilia, or Non-Neoplastic Hematologic Conditions.

Study arms and study modules are developed to advance the exploration of blood disorders disease specific insights by ATHN and its partners. Arms may branch off into product-specific data collection via Modules to be collected during the study, in conjunction with planned study assessments.

ATHN Transcends

Co- Principal Investigators:

Tammuella Chrisentery-Singleton, MD Ochsner Clinic Foundation American Thrombosis and Hemostasis Network

Michael Recht, MD, PhD, MBA Yale University School of Medicine National Bleeding Disorders Foundation

PUPs Arm

Principal Investigator:

Shannon Carpenter, MD, MS University of Missouri Kansas City School of Medicine Children's Mercy Hospital

ALTUVIIO Module

Principal Investigator:

Shannon Carpenter, MD, MS University of Missouri Kansas City School of Medicine Children's Mercy Hospital

INHIBIT Module

Principal Investigator:

Nicoletta Machin DO, MS Hemophilia Center of Western Pennsylvania University of Pittsburgh Medical Center

Hemophilia Natural History Arm

Principal Investigator:

Fernando Corrales-Medina, MD, FAAP University of Miami-Comprehensive Hemophilia Treatment Center University of Miami-Miller School of Medicine

Rebinyn Module

Co-Principal Investigators:

Lauren Amos, MD University of Missouri Kansas City School of Medicine Children's Mercy Hospital

Guy Young, MD University of Southern California Children's Hospital Los Angeles

Distress Module

Principal Investigator:

Tammuella Chrisentery-Singleton, MD Ochsner Clinic Foundation American Thrombosis and Hemostasis Network

Hemlibra Module

Principal Investigator:

Fernando Corrales-Medina, MD, FAAP University of Miami-Comprehensive Hemophilia Treatment Center University of Miami-Miller School of Medicine

Hemophilia Gene Therapy Outcomes Arm:

Co-Principal Investigators:

Janice M. Staber, MD Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Children's Hospital

Ulrike M. Reiss, MD Hemophilia Treatment Center St. Jude's Children's Research Hospital

HEMGENIX Module

Co-Principal Investigators:

Janice M. Staber, MD Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Children's Hospital

Ulrike M. Reiss, MD Hemophilia Treatment Center, St. Jude's Children's Research Hospital

Severe VWD Natural History Arm:

Co-Principal Investigators:

Robert F. Sidonio, Jr., MD, MSc Aflac Cancer and Blood Disorders Center, Hemophilia of Georgia Center for Bleeding and Clotting Disorders

Angela C. Weyand, MD C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor

Congenital Platelet Disorders Natural History Arm:

Principal Investigator Sanjay Ahuja, MD Innovative Hematology, Indiana Hemophilia & Thrombosis Center

Glanzmann Thrombasthenia Module:

Co-Principal Investigators:

Divya Citla-Sridhar, MD University of Arkansas for Medical Sciences Arkansas Children's Hospital

Meera Chitlur, MD Central Michigan University, Children's Hospital of Michigan

Hemophilia Cohort

This cohort includes three Arms and six Modules:

Previously Untreated Patients (PUPs) Arm This is a pediatric focused Arm of PUPs with hemophilia A or B of any severity.

Efanestoctocog alfa (ALTUVIIIO®) Module The purpose is to investigate the safety, tolerability, and effectiveness of efanesoctocog alfa (ALTUVIIIO®) in PUPs with severe hemophilia A.

INHIBIT Module This is an observational study assessing the rate of inhibitor formation in young children with severe hemophilia A in the current treatment era.

Hemophilia Natural History Arm This Arm is investigating the safety, effectiveness, and practice of treatment for people with hemophilia.

Emicizumab (Hemlibra®) Module All participants treated with Hemlibra® are eligible to participate.

Distress Module Participants with Congenital Hemophilia A or B, 18 years of age or older, will be followed longitudinally for 2 years or from time of enrollment for a total planned study duration of 3 years

Nonacog beta pegol (Rebinyn®) Module The Rebinyn® Module is a prospective study in hemophilia B participants without inhibitors.

Hemophilia Gene Therapy Outcomes Arm This Arm is investigating the safety and effectiveness of gene therapy in people with hemophilia.

Etranacogene dezaparvovec (HEMGENIX®) Module This is an observational study to characterize the effectiveness and safety of HEMGENIX® in participants with hemophilia B.

Congenital Platelet Disorders (CPD) Natural History Arm:

The CPD Arm is investigating the natural history of the safety and efficacy of hemostatic therapies (such as platelet transfusions, desmopressin, antifibrinolytics, recombinant factor VIIa) in the prevention or treatment of bleeding events (on demand, surgery, prophylaxis) in adult and pediatric participants with inherited congenital platelet disorders..

Glanzmann Thrombasthenia (GT) Module:

This Module is a study of bleeding symptoms, treatments, and treatment outcomes in patients with Glanzmann thrombasthenia.

Von Willebrand Disease Cohort No arms or modules open at this time.

Rare Disorders Cohort No arms or modules open at this time.

Bleeding NOS No arms or modules open at this time.

Thrombosis/Thrombophilia No arms or modules open at this time.

Non-Neoplastic Hematologic Conditions No arms or modules open at this time.

Study Type

Observational

Enrollment (Estimated)

3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Carol Fedor, ND, RN, CCRC
  • Phone Number: 122 800-360-2846
  • Email: cfedor@athn.org

Study Contact Backup

Study Locations

  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85016
        • Recruiting
        • Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital
        • Contact:
        • Principal Investigator:
          • Shanna White, MD
    • Arkansas
      • Little Rock, Arkansas, United States, 72202
        • Recruiting
        • Arkansas Center for Bleeding Disorders
        • Contact:
        • Principal Investigator:
          • Shelley Crary, MD
    • California
      • Los Angeles, California, United States, 90007
        • Recruiting
        • Orthopaedic Institute for Children HTC
        • Principal Investigator:
          • Doris Quon, MD
        • Contact:
      • Los Angeles, California, United States, 90027-6016
        • Recruiting
        • Childrens Hospital Los Angeles
        • Principal Investigator:
          • Guy Young, MD
        • Contact:
      • Oakland, California, United States, 94610
        • Recruiting
        • UCSF Benioff Children's Hospital Oakland
        • Contact:
        • Principal Investigator:
          • Alison Matsunaga, MD
      • Sacramento, California, United States, 95817
        • Recruiting
        • University of California at Davis Hemophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Kim Schafer, RN, MSN, FNP
      • San Bernardino, California, United States, 92408
        • Recruiting
        • Loma Linda Hemoglobinopathy and Inherited Bleeding Disorder Program
        • Contact:
          • Rosa Rivas
          • Phone Number: 909-651-1910
        • Principal Investigator:
          • Akshat Jain, MD
      • San Diego, California, United States, 92123
        • Recruiting
        • Rady Children's Hospital San Diego
        • Contact:
        • Principal Investigator:
          • Julie Jaffray, MD
      • San Diego, California, United States, 92121
        • Recruiting
        • Hemophilia & Thrombosis Treatment Center at UC San Diego Health
        • Contact:
        • Principal Investigator:
          • Annette Von Drygalski, MD
      • San Francisco, California, United States, 94143
        • Recruiting
        • University of California, San Francisco Hemophilia & Thrombosis Center
        • Principal Investigator:
          • Andrew Leavitt, MD
        • Contact:
    • Connecticut
      • Hartford, Connecticut, United States, 06106
      • New Haven, Connecticut, United States, 06520
        • Recruiting
        • Yale Hemophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Stephanie Prozora, MD
    • Delaware
      • Wilmington, Delaware, United States, 19801
        • Recruiting
        • Delaware Hemophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Corrina Schultz, MD
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20007
        • Recruiting
        • Georgetown University
        • Contact:
        • Principal Investigator:
          • Craig Kessler, MD
      • Washington D.C., District of Columbia, United States, 20010
        • Recruiting
        • Children's National Hemophilia Center
        • Contact:
        • Principal Investigator:
          • Michael Guerrera, MD
    • Florida
      • Gainesville, Florida, United States, 32610
        • Recruiting
        • University of Florida Hemophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Tung Wynn, MD
      • Miami, Florida, United States, 33136
        • Recruiting
        • University of Miami Comprehensive Hemophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Fernando Corrales-Medina, MD
      • Orlando, Florida, United States, 32806
        • Not yet recruiting
        • Arnold Palmer Hospital for Children - The Haley Center for Children's Cancer and Blood Disorders
        • Principal Investigator:
          • Shveta Gupta, MD
        • Contact:
      • St. Petersburg, Florida, United States, 33701
        • Recruiting
        • Johns Hopkins All Children's Hospital
        • Contact:
        • Principal Investigator:
          • Irmel Ayala, MD
      • Tampa, Florida, United States, 33607
        • Recruiting
        • St. Joseph's Hospital Center for Bleeding & Clotting Disorders
        • Contact:
        • Principal Investigator:
          • Erin Cockrell, MD
    • Georgia
      • Atlanta, Georgia, United States, 30308
        • Recruiting
        • Comprehensive Bleeding Disorders Center at Emory University and Children's Healthcare of Atlanta
        • Contact:
        • Principal Investigator:
          • Christine Kempton, MD
      • Atlanta, Georgia, United States, 30322
        • Recruiting
        • Emory/Children's Health Care of Atlanta
        • Principal Investigator:
          • Robert Sidonio, Jr, MD
        • Contact:
      • Savannah, Georgia, United States, 31403
        • Recruiting
        • Memorial Health University Medical Center
        • Contact:
        • Principal Investigator:
          • James Yarnall, MD, MPH
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • Rush University Medical Center
        • Principal Investigator:
          • Mindy Simpson, MD
        • Contact:
      • Peoria, Illinois, United States, 61664
        • Recruiting
        • Bleeding and Clotting Disorders Institute
        • Principal Investigator:
          • Jonathan Roberts, MD
        • Contact:
    • Indiana
      • Indianapolis, Indiana, United States, 46260
        • Recruiting
        • Indiana Hemophilia and Thrombosis Center
        • Principal Investigator:
          • Amy Shapiro, MD
        • Contact:
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • Recruiting
        • Iowa Hemophilia and Thrombosis Center
        • Principal Investigator:
          • Janice Staber, MD
        • Contact:
    • Louisiana
      • New Orleans, Louisiana, United States, 70112
        • Recruiting
        • Louisiana Center for Bleeding and Clotting Disorders, Tulane University
        • Contact:
        • Principal Investigator:
          • Maissaa Janbain, MD
    • Maine
      • Scarborough, Maine, United States, 04074
        • Recruiting
        • Maine Hemophilia and Thrombosis Center
        • Principal Investigator:
          • Eric Larsen, MD
        • Contact:
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Recruiting
        • Johns Hopkins University Hemophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Jennifer Keates-Baleeiro, MD
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Not yet recruiting
        • Massachusetts General Hospital Comprehensive Hemophilia and Thrombosis Treatment Center
        • Principal Investigator:
          • Eric Grabowski, MD
        • Contact:
    • Michigan
      • Detroit, Michigan, United States, 48201
        • Recruiting
        • Central Michigan Children's Hospital of Michigan
        • Principal Investigator:
          • Madhvi Rajpurkar, MD
        • Contact:
      • Detroit, Michigan, United States, 48202
        • Recruiting
        • Henry Ford Health System Bleeding and Thrombosis Treatment Center
        • Principal Investigator:
          • Philip Kuriakose, MD
        • Contact:
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Recruiting
        • Mayo Comprehensive Hemophilia Center
        • Contact:
        • Principal Investigator:
          • Meera Sridharah, MD
    • Missouri
      • Kansas City, Missouri, United States, 64108
        • Recruiting
        • Children's Mercy Hospital - Kansas City
        • Principal Investigator:
          • Shannon Carpenter, MD
        • Contact:
      • St Louis, Missouri, United States, 63104
        • Recruiting
        • The John Bouhasin Center for Children with Bleeding Disorders
        • Principal Investigator:
          • John Puetz, MD
        • Contact:
    • Nevada
      • Las Vegas, Nevada, United States, 89135
        • Recruiting
        • Cure 4 the Kids Foundation
        • Contact:
        • Principal Investigator:
          • Aimee Foord, MD
      • Reno, Nevada, United States, 89509
        • Recruiting
        • Hemostasis and Thrombosis Center of Nevada
        • Contact:
        • Principal Investigator:
          • Daisy Cortes, MD
    • New Jersey
      • Newark, New Jersey, United States, 07122
        • Recruiting
        • Newark Beth Israel Medical Center - Hemophilia Center
        • Contact:
        • Principal Investigator:
          • Alice Cohen, MD
    • New Mexico
      • Albuquerque, New Mexico, United States, 87131
        • Recruiting
        • University of New Mexico Ted R. Montoya Hemophilia & Thrombosis Program
        • Contact:
        • Principal Investigator:
          • Shirley Abraham, MD
    • New York
      • Buffalo, New York, United States, 14202
        • Recruiting
        • Western New York BloodCare
        • Contact:
        • Principal Investigator:
          • Beverly Schaefer, MD
      • Hyde Park, New York, United States, 11040
        • Recruiting
        • Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center
        • Principal Investigator:
          • Suchitra Acharya, MD
        • Contact:
      • New York, New York, United States, 10065
        • Recruiting
        • Weill Cornell Medical College - New York Presbyterian Hospital
        • Principal Investigator:
          • Catherine McGuinn, MD
        • Contact:
      • Rochester, New York, United States, 14626
        • Recruiting
        • American Thrombosis and Hemostasis Network
        • Principal Investigator:
          • Tammuella Chrisentery-Singleton, MD
        • Contact:
        • Contact:
      • The Bronx, New York, United States, 10461
        • Recruiting
        • Montefiore Medical Center
        • Principal Investigator:
          • Henny Billett, MD
        • Contact:
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27517
        • Recruiting
        • Comprehensive Hemophilia Treatment Center, University of North Carolina at Chapel Hill
        • Principal Investigator:
          • Nigel Key, MD
        • Contact:
      • Charlotte, North Carolina, United States, 28204
        • Recruiting
        • St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital
        • Principal Investigator:
          • Christine Bolen, MD
        • Contact:
      • Greenville, North Carolina, United States, 27834
        • Recruiting
        • East Carolina University Hemophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Beng Fuh, MD
      • Winston-Salem, North Carolina, United States, 27157
        • Recruiting
        • Wake Forest University Health Sciences
        • Contact:
        • Principal Investigator:
          • Amanda Blair, MD
    • Ohio
      • Akron, Ohio, United States, 44308
        • Recruiting
        • Akron Children's Hospital - Showers Center for Cancer & Blood Disorders
        • Principal Investigator:
          • Nicole Kendel, MD
        • Contact:
      • Cincinnati, Ohio, United States, 45229
        • Recruiting
        • Cincinnati Children's Hospital Medical Center, Hemophilia & Thrombosis Center
        • Contact:
        • Principal Investigator:
          • Cristina Tarango, MD
      • Cincinnati, Ohio, United States, 45267
        • Recruiting
        • University of Cincinnati Medical Center Hemophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Kristine Karkoska, MD
      • Cleveland, Ohio, United States, 44106
        • Recruiting
        • University Hospitals Health System Cleveland
        • Principal Investigator:
          • John Letterio, MD
        • Contact:
      • Columbus, Ohio, United States, 43205
        • Recruiting
        • Nationwide Children's Hospital Columbus
        • Principal Investigator:
          • Amy Dunn, MD
        • Contact:
      • Dayton, Ohio, United States, 45404
        • Recruiting
        • Dayton Children's Hemostasis and Thrombosis Center
        • Contact:
        • Principal Investigator:
          • Jordan Wright, MD
      • Toledo, Ohio, United States, 43606
        • Recruiting
        • Northwest Ohio Hemophilia Treatment Center at the Toledo Hospital
        • Contact:
        • Principal Investigator:
          • Dagmar Stein, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Recruiting
        • Children's Hospital of Philadelphia
        • Principal Investigator:
          • Leslie Raffini, MD
        • Contact:
      • Philadelphia, Pennsylvania, United States, 19104
        • Recruiting
        • Penn Comprehensive Hemophilia and Thrombophilia Program/Hospital of the University of Pennsylvania
        • Contact:
        • Principal Investigator:
          • Adam Cuker, MD
      • Pittsburgh, Pennsylvania, United States, 15213
        • Recruiting
        • Hemophilia Center of Western Pennsylvania
        • Contact:
        • Principal Investigator:
          • Nicoletta Machin, MD
    • Rhode Island
      • Providence, Rhode Island, United States, 02903
        • Recruiting
        • Rhode Island Hospital Hemostasis and Thrombosis Center
        • Principal Investigator:
          • Salley Pels, MD
        • Contact:
    • Tennessee
      • Memphis, Tennessee, United States, 38105
        • Recruiting
        • St. Jude Children's Research Hospital
        • Principal Investigator:
          • Ulrike Reiss, MD
        • Contact:
      • Nashville, Tennessee, United States, 37212
        • Recruiting
        • Vanderbilt University Medical Center
        • Principal Investigator:
          • Shannon Walker, MD
        • Contact:
    • Texas
      • Austin, Texas, United States, 78723
        • Recruiting
        • Children's Blood and Cancer Center of Central Texas
        • Contact:
        • Principal Investigator:
          • Arun Gurunathan, MD
      • Dallas, Texas, United States, 75235
        • Recruiting
        • North Texas Hemophilia and Thrombosis Program - Pediatric Program / Center for Cancer & Blood Disorders
        • Contact:
        • Principal Investigator:
          • Ayeshia Zia, MD
      • Dallas, Texas, United States, 75390
        • Recruiting
        • North Texas Comprehensive Hemophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Yu-Min Shen, MD
      • Houston, Texas, United States, 77030
        • Recruiting
        • Gulf States Hemophilia and Thrombophilia Center
        • Contact:
        • Principal Investigator:
          • Miguel A. Escobar, MD
      • Houston, Texas, United States, 77030
        • Recruiting
        • Texas Children's Hemophilia & Thrombosis Center/Baylor College of Medicine
        • Principal Investigator:
          • Clay Cohen, MD
        • Contact:
      • San Antonio, Texas, United States, 78229
        • Recruiting
        • South Texas Comprehensive Hemophilia and Thrombophilia Treatment Center
        • Contact:
        • Principal Investigator:
          • Deanna Maida, MD
    • Washington
      • Seattle, Washington, United States, 98101
        • Recruiting
        • Washington Center for Bleeding Disorders
        • Contact:
        • Principal Investigator:
          • Rebecca Kruse-Jarres, MD
    • Wisconsin
      • Green Bay, Wisconsin, United States, 54311
        • Recruiting
        • Hemophilia Outreach Center Green Bay
        • Contact:
        • Principal Investigator:
          • Kenneth Friedman, MD
      • Milwaukee, Wisconsin, United States, 53226
        • Recruiting
        • Comprehensive Center for Bleeding Disorders
        • Principal Investigator:
          • Lynn Malec, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

This is a real-world study in which participants with congenital or acquired blood disorders will be enrolled.

Description

Participants who meet the following inclusion criteria and none of the exclusion criteria are eligible for enrollment in one of the open disease-specific arms.

Inclusion Criteria:

  1. Any age
  2. Having a congenital or acquired blood disorder; or
  3. Having a bleeding phenotype as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score with an unknown diagnosis; or
  4. Connective tissue disorder with bleeding tendency as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score.
  5. Eligible for a currently active disease-specific arm.
  6. Concurrent enrollment in the ATHNdataset or current ATHNdataset participant.

Exclusion Criteria:

1. Does not qualify for inclusion in a currently activedisease-specific arm; participants may be eligible to enroll as future cohorts and arms are activated; 2. Unable to give informed consent or assent 3. Unwilling to perform study procedures

Cohort Participant Selection

Each participant is to be enrolled in the cohort for which they qualify as defined below.

Hemophilia Cohort

Inclusion Criteria:

Participants who meet any of the following inclusion criteria are eligible for enrollment into this cohort:

  1. Factor VIII or factor IX activity <50%, without another explanation for low clotting factor other than congenital hemophilia or being a known carrier for congenital hemophilia; OR
  2. Carrier for congenital hemophilia with a factor VIII >=50% or factor IX activity >=50% with or without a bleeding phenotype as indicated by an ISTH Bleeding Assessment Tool score of ≥4 for adult males, ≥6 for adult females, or ≥3 for children younger than 18 years OR
  3. Known congenital hemophilia that have a factor level >50% after receiving vector, OR 4. Acquired hemophilia.

Exclusion Criteria:

None

Von Willebrand Disease Cohort

Inclusion Criteria:

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Meeting the definition of VWD or low VWF per most recent international guidelines

Exclusion Criteria:

None

Congenital Platelet Disorders Cohort

Inclusion Criteria:

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

  1. Abnormalities of platelet function a. Glanzmann thrombasthenia (GPIIb or GPIIIa) b. Bernard-Soulier syndrome (GPIbalpha, GPIbbeta, or GPIX)
  2. Abnormalities of platelet granules
  3. Abnormalities of platelet signal transduction
  4. Abnormalities of platelet secretion
  5. Collagen Receptor Defect
  6. ADP Receptor Defect
  7. Thromboxane Receptor Defect
  8. Giant Platelet Disorder
  9. Abnormalities in platelet aggregation testing due to another or unknown cause (not drug related)

Exclusion Criteria:

1. Platelet disorders secondary to medications or other substances

Rare Disorders Cohort

Inclusion Criteria:

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Have an established Rare Coagulation Disorder (RCD) diagnosis of one of the following:

  1. PAI-1 deficiency
  2. Factor I, II, V, VII, X, XI, XIII deficiencies
  3. Combined FV and FVIII deficiency
  4. Plasminogen deficiency
  5. Decreased tissue plasminogen activator
  6. Afibrinogenemia/hypofibrinogenemia/dysfibrinogenemia
  7. Thrombotic Thrombocytopenia Purpura or Congenital Hemolytic Uremic Syndrome
  8. Wiskott-Aldrich
  9. Methylenetetrahydrofolate Reductase Deficiency

Exclusion Criteria:

None

Bleeding NOS Cohort

Inclusion Criteria:

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

  1. Have a bleeding phenotype as indicated by an ISTH Bleeding Assessment Tool score of ≥4 for adult males, ≥6 for adult females, or ≥3 for children younger than 18 years with an unknown diagnosis, OR
  2. Connective tissue disorder with bleeding tendency as indicated by an ISTH Bleeding Assessment Tool score of ≥4 for adult males, ≥6 for adult females, or ≥3 for children younger than 18 years.

Exclusion Criteria:

None

Thrombosis/Thrombophilia Cohort

Inclusion Criteria

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Have a prior history of arterial or venous thrombosis. 2. Participants with a known congenital or acquired thrombophilia with or without thrombosis.

a. Common congenital thrombophilias: i. Protein C deficiency ii. Protein S deficiency iii. Antithrombin deficiency iv. Factor V Leiden v. Prothrombin gene mutation b. Rare genetic factors i. Hyperhomocysteinemia c. Indeterminate genetic factors i. Elevated factor VIII ii. Elevated factor IX iii. Elevated factor XI iv. Elevated lipoprotein (a) d. Acquired thrombophilias i. Lupus anticoagulant ii. Anti-cardiolipin antibodies/Beta2 glycoprotein antibodies iii. Antiphospholipid syndrome

Exclusion Criteria Acquired thrombophilia secondary to medications (birth control pills or hormone replacement therapy), overweight or obesity, smoking, cancer, pregnancy, surgery, injury, prolonged inactivity/bedrest, heart failure, inflammatory bowel disease, or kidney disease

Non-Neoplastic Hematologic Conditions Cohort

Inclusion Criteria

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Having any congenital or acquired non-neoplastic hematologic disorder not included in any other cohort

Exclusion Criteria None

Arm/Module Participant Selection

Previously Untreated Patients Arm

Inclusion Criteria:

  1. Diagnosis of congenital hemophilia A (FVIII <40%) or hemophilia B (FIX <40% or below lower limit for age)
  2. Age <18 years at time of enrollment
  3. Parent or authorized guardian or legally authorized representative (LAR) can provide informed consent
  4. Care established at one of the ATHN Transcends participating HTCs
  5. Clotting Factor Concentrate (CFC) exposure, fresh frozen plasma (FFP), cryoprecipitate, and single donor platelets <3 exposure days (ED)

Exclusion Criteria

  1. Concomitant diagnosis with another bleeding disorder
  2. History of a confirmed, positive inhibitor

INHIBIT Module

Inclusion Criteria:

1. Diagnosis of severe factor VIII deficiency with baseline factor VIII level <1% 2. Initiating or plan to initiate prophylaxis with emicizumab or factor replacement 3. Factor concentrate exposure, Fresh Frozen Plasma (FFP), cryoprecipitate, and single donor platelets ≤3 EDs 4. ≤5 years of age

Exclusion Criteria

  1. Concomitant diagnosis with bleeding disorder other than hemophilia A
  2. Immune disorder
  3. Previous history or presence of factor VIII inhibitor. A confirmed, positive inhibitor is defined as two consecutive positive inhibitor titers (≥ 0.6 BU) that result in changes in treatment recommendations.

Efanesoctocog alfa (ALTUVIIIO®) Module

Inclusion criteria:

  1. Ability of the potential participant's legally authorized representative (e.g., their parent or legal guardian) to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local participant privacy regulation.
  2. People with severe HA with a baseline FVIII activity of less than 1%. (While inclusion for participation in ATHN Transcends lists <5% FVIII activity, this proposed module will limit enrollment to people with FVIII activity levels of <1%.) Other severities may be included per ATHN Transcends PI approval.
  3. <18 years of age.
  4. No history of a confirmed, positive FVIII inhibitor.
  5. Sex assigned at birth of male, female, or intersex.
  6. Participants should have no more than three (3) exposure days of blood products (fresh frozen plasma, cryoprecipitate, or platelets), no more than three (3) doses of any FVIII concentrate other than efanesoctocog alfa, and up to three (3) doses of efanesoctocog alfa prior to enrollment.
  7. Site PI confirmed all inclusion criteria has been met.

Exclusion criteria:

  1. Not meeting all the inclusion criteria; confirmed by site PI.
  2. Any exposure to blood products or FVIII replacement products except as described in the inclusion criteria.
  3. History of positive inhibitor testing.
  4. History of hypersensitivity reactions associated with efanesoctocog alfa administration.
  5. Other coagulation disorder(s) in addition to Hemophilia A.
  6. Any concurrent clinically significant major disease such as cancer that, in the opinion of the investigator, would make the participant unsuitable for enrollment.
  7. Concurrent systemic treatment with chemotherapy and/or other immunosuppressant medications. Use of corticosteroids for the treatment of asthma or management of acute allergic or otherwise life-threatening episodes is allowed except for systemic corticosteroid treatment given to children daily or on an alternate day schedule at > 2 mg/kg/day of prednisone or its equivalent or > 20 mg/day if the duration is longer than 14 days.
  8. Enrollment in a concurrent clinical interventional drug study.
  9. Intake of an Investigational Medicinal Product within three (3) months prior to inclusion in this study.
  10. Inability to comply with study requirements.
  11. Other, unspecified reasons that, in the investigator's opinion, make the participant unsuitable for enrollment.

Hemophilia Natural History Arm

Inclusion Criteria

  1. Congenital or acquired hemophilia A or B of any severity with or without inhibitors receiving a current therapy, a non-factor product, or for whom use of a non-factor product is a possibility, OR
  2. Females of any age, with confirmed congenital hemophilia A or B carrier status with genetic mutational analysis and any factor level.

Exclusion Criteria

  1. Presence of any known bleeding disorder other than congenital hemophilia A or B
  2. Presence of concurrent hemophilia and a second hemostatic defect (low von Willebrand Factor (vWF) without vWD diagnosis is not excluded)
  3. Unable or unwilling to comply with the study arm protocol.

Nonacog beta pegol (Rebinyn®) Module

Inclusion Criteria:

  1. Has provided signed written consent for the nonacog beta pegol (Rebinyn®)Module before any study-related activities.
  2. Male participants, at any age with hemophilia B, naïve or minimally exposed (up to 3 EDs) to nonacog beta pegol treatment at time of study enrollment. Additional doses may be allowable per ATHN Transcends PI approval.
  3. Decision to initiate continuous prophylaxis treatment with commercially available nonacog beta pegol has been made by the participant(s)/Legally Authorized Representative(s) (LAR(s)) and the treating physician before and independently from the decision to include the participant in this study.

Exclusion Criteria:

  1. Previous participation in this study. Participation is defined as having given informed consent in this study.
  2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation, including a diagnosis or suspicion of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) per the discretion of the Principal Investigator.
  3. Known or suspected hypersensitivity to nonacog beta pegol or related products.
  4. Clinical suspicion or presence of FIX inhibitor at time of inclusion.
  5. Inability or unwillingness to undergo neurological assessment/structured developmental history.

Emicizumab (Hemlibra®) Module

Inclusion Criteria:

  1. Participant currently treated with emicizumab (Hemlibra®)
  2. Currently enrolled in the Hemophilia Natural History Arm of ATHN Transcends

Exclusion Criteria:

1. Unable or unwilling to comply with the protocol

Distress Module

Inclusion Criteria:

  1. Congenital hemophilia A or B of any severity with or without inhibitors receiving a current therapy, a non-factor product, or for whom use of a non-factor product is a possibility
  2. Age 18 years of age or older
  3. English speaking

Exclusion Criteria:

  1. Presence of any known bleeding disorder other than congenital hemophilia A or B;
  2. Presence of concurrent hemophilia and a second hemostatic defect (low von Willebrand Factor (vWF) without vWD diagnosis is not excluded); and
  3. Unable or unwilling to comply with the study arm protocol

Hemophilia Gene Therapy Outcomes Arm

Inclusion Criteria

  1. Hemophilia A or B of any severity with or without inhibitors having received or will receive a hemophilia gene transfer product in the next 6 months.
  2. Age 18 years and older.
  3. Able to give informed consent.

Exclusion Criteria None

Etranacogene dezaparvovec (HEMGENIX®) Module

Inclusion Criteria:

Etranacogene dezaparvovec (HEMGENIX®) Cohort

  1. Age 18 years of age or older
  2. Treatment with commercial etranacogene dezaparvovec (HEMGENIX®)
  3. Have provided signed written informed consent within 3 months before or within 6 months after etranacogene dezaparvovec (HEMGENIX®) treatment, or within 6 months of when the study is initiated at the treating site.

FIX Prophylaxis Cohort

  1. Age 18 years of age or older
  2. Treatment with FIX prophylaxis therapy
  3. Has provided signed written consent at any time for ATHN Transcends Study

Exclusion Criteria, both cohorts:

1. Have been treated with etranacogene dezaparvovec in a clinical trial prior to commercial availability. These patients are still eligible for enrollment in the Gene Therapy Outcomes Arm, and their data may be collected for separate analysis.

Congenital Platelet Disorders Arm

Inclusion Criteria

  1. Platelet adhesion defect

    1. Bernard Soulier syndrome (Defective GPIb-IX-V receptor, impaired adhesion to vWF)
    2. Velocardio-facial syndrome/DiGeorge syndrome (Defective GPIb-IX-V receptor)
    3. Platelet type vWD (Defective GPIb-IX-V, gain of function interaction between vWF-GP1bα)

  2. Platelet aggregation defect

    1. Glanzmann thrombasthenia (Defective integrin αIIbβ3 (GPIIb/IIIa)
    2. Platelet aggregation defect, NOS

  3. Agonist receptor defects

    1. Epinephrine
    2. ADP
    3. Collagen
    4. Thromboxane A2

  4. Platelet signaling defects

    1. Cyclooxygenase deficiency (PTGS1 mutation)
    2. Phospholipase A2 deficiency
    3. Thromboxane synthase deficiency (TBXAS1 mutation)
    4. G protein activation defect (GNAS mutation)
    5. Scott syndrome (defect in phosphatidyl serine translocation)

  5. Platelet Granule disorders

    1. Dense granule storage pool disorder

      • Hermansky Pudlak syndrome
      • Chediak Higashi syndrome
      • Griscelli syndrome

    2. Alpha granule storage pool disorder

      • Grey platelet syndrome
      • Arthrogryposis-Renal Dysfunction-Cholestasis (ARC) syndrome
      • Quebec platelet disorder
      • Paris-Trousseau syndrome
    3. Combined alpha delta granule deficiency

  6. Platelet cytoskeletal structure defects

    1. Wiskott Aldrich syndrome

    2. MYH9 associated disorders (myosin heavy chain)

      • May Hegglin syndrome
      • Fechtner syndrome
      • Sebastian syndrome
      • Epstein syndrome

    3. Other mutations

      • FLNA mutations (Filamin)
      • DIAPH1 (Actin and microtubules)
      • ACTN1 (alpha actinin)
      • TPM4 (tropomyosin)
      • TUBB1 (beta tubulin)

  7. Other Congenital thrombocytopenias

    1. Familial platelet disorders and predisposition to AML (RUNX1)
    2. X linked thrombocytopenia with dyserythropoiesis (GATA1)
    3. Congenital amegakaryocytic thrombocytopenia (MPL)

Exclusion Criteria

  1. Diagnosis of von Willebrand Disease (Meeting the definition of vWD or low vWF per most recent international guidelines)
  2. Diagnosis of Hemophilia A or Hemophilia B (Factor VIII or IX ≤ 40%)

Glanzmann Thrombasthenia (GT) Module

Inclusion Criteria

  1. Participant has signed the informed consent/assent form
  2. Participant has flow cytometry or aggregometry or genetics confirmed GT
  3. Participant is willing to perform study procedures, including daily bleed tracking for 3 months and further if requested
  4. Participants are 2 years or older at time of consent

Exclusion Criteria None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Congenital Platelet Disorders

This cohort includes one Arm and Module:

Congenital Platelet Disorders (CPD) Natural History Arm Glanzmann Thrombasthenia (GT) Module
Von Willebrand Disease
No arms or modules
Rare Disorders
No arms or modules
Bleeding NOS
No arms or modules
Thrombosis/Thrombophilia
No arms or modules
Non-Neoplastic Hematologic Conditions
No arms or modules
Hemophilia

This cohort includes three Arms and six Modules:

Previously Untreated Patients (PUPs) Arm

Efanestoctocog alfa (ALTUVIIIO®) Module

INHIBIT Module

Hemophilia Natural History Arm

Emicizumab (Hemlibra®) Module

Nonacog beta pegol (Rebinyn®)Module

Distress Module

Hemophilia Gene Therapy Outcomes Arm

Etranacogene dezaparvovec (HEMGENIX®) Module

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To determine the safety of therapies used in the treatment of participants with congenital or acquired non-neoplastic, bleeding and clotting disorders and connective tissue disorders with bleeding tendency (blood disorders).
Time Frame: 15 years

Safety will be measured by those events in the European Safety Surveillance (EUHASS)1:

  1. Allergic or other acute events
  2. Treatment-emergent side effects of therapy
  3. Transfusion transmitted infections
  4. Inhibitor development
  5. Thrombosis
  6. Cardiovascular events
  7. Malignancies
  8. Neurological events
  9. Death

In addition to the modified EUHASS endpoints, the following events will be collected as adverse events of special interest (AESI):

  1. The occurrence of thrombotic microangiopathies, injection site reactions and cases of potential drug-induced liver injury
  2. The development of anti-drug antibodies, to be measured and confirmed, if feasible
  3. Severe, unanticipated bleeding
  4. Hospitalizations
  5. Glomerulonephritis
  6. Any arm or module-specific AESI as stated in their corresponding Safety Assessment section

Additional safety events of interest may be collected.
15 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To establish a platform to support study arms and modules for participants with blood disorders.
Time Frame: 15 years
For each Arm, a brief set of data elements of interests will be developed and reported for study participants.
15 years
To describe medication dosing regimens in participants with blood disorders.
Time Frame: 15 years

This objective will be evaluated by:

  1. Determining the number of participants who initiate and/or switch treatment with non-factor products and participants' reasons for initiating and/or switching treatment with non-factor products
  2. Determining the number of participants who do not initiate treatment with non-factor products
  3. Determining the number of participants who switch between different non-factor products and the participants' reasons for switching non-factor products
  4. Determining the number of participants who discontinue treatment with non-factor products and participants' reasons for discontinuing treatment with non-factor products
15 years
To describe real-world effectiveness of therapies used for participants with blood disorders.
Time Frame: 15 years
  1. Health care utilization as measured by number and type of visits and hospitalizations per year
  2. Patient reported outcomes (PROs) as measured by the Patient Reported Outcomes Measurement Information System (PROMIS®) Profile 29/25/Parent Proxy, Global Adherence Rating (GAR) (ages 7 and older), CATCH, and EQ-5D5L
15 years
To grow and evolve the ATHN Transcends Biorepository for current and future research through the collection of biospecimens from participants enrolled on this protocol
Time Frame: 15 years
All participants have the option to provide consent to have specimens stored in the ATHN Transcends Biorepository. Samples will be collected as needed, including at the Baseline Visit, Annual Visit, and at Study Exit Visit (if not collected at your Annual Visit), as funding allows.
15 years
To describe bleeding events, changes in overall bleeding, and annualized bleeding rate (ABR) as measured by individual bleeding components.
Time Frame: 15 years
This objective will be calculated per ISTH Bleeding Assessment Tool (ISTH BAT), participant completed Treatment and Bleed log, and if applicable, a Pictorial Bleeding Assessment Chart (PBAC), for relevant diagnoses.
15 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
To describe real-world effectiveness of therapies by evaluating for Goal attainment
Time Frame: 15 years
Measured by GOAL-Hem for those participants that opt into this measurement
15 years
To describe real-world effectiveness of therapies by evaluating for Patient Reported Outcomes (PROs)
Time Frame: 15 years
Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Profile 29/25/Parent Proxy
15 years
To describe real-world effectiveness of therapies by evaluating treatment adherence
Time Frame: 15 years
Measured by the Global Adherence Rating (GAR)
15 years
To describe real-world effectiveness of therapies by evaluating health utility
Time Frame: 15 years
Measured by the EQ-5D-5L
15 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

American Thrombosis and Hemostasis Network

Collaborators

Novo Nordisk A/S
Sanofi
Pfizer
Genentech, Inc.
CSL Behring
Hemophilia of Georgia, Inc.
Hemab ApS

Investigators

  • Principal Investigator: Michael Recht, MD, PhD, MBA, Yale University School of Medicine & National Bleeding Disorders Foundation
  • Principal Investigator: Tammuella Chrisentery-Singleton, MD, ATHN, Ochsner Clinic Foundation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 30, 2020

Primary Completion (Estimated)

June 1, 2035

Study Completion (Estimated)

December 1, 2035

Study Registration Dates

First Submitted

May 11, 2020

First Submitted That Met QC Criteria

May 20, 2020

First Posted (Actual)

May 21, 2020

Study Record Updates

Last Update Posted (Estimated)

January 12, 2026

Last Update Submitted That Met QC Criteria

January 9, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ATHN Transcends

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemophilia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe